

Mediclinic International plc
 (Incorporated in England and Wales)
 Company Number: 08338604
 LSE Share Code: MDC
 JSE Share Code: MEI
 NSX Share Code: MEP
 ISIN: GB00B8HX8Z88
 LEI: 2138002S5BSBIZTD5I60
 South African income tax number: 9432434182
 ('Mediclinic', the 'Company', or the 'Group')

21 June 2022

NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM

Vesting of awards under the Company's Long-term Incentive ('LTI') Plan

This notification sets out details of the vesting of awards over ordinary shares in Mediclinic ('Shares') granted to persons discharging managerial responsibilities ('PDMRs') on 19 June 2019 under the Company's LTI Plan (the 'LTI Plan Awards'), in accordance with the remuneration policy approved by shareholders in July 2017. These awards were structured as conditional awards vesting on the third anniversary of the date of grant, subject to the satisfaction of performance conditions over the three-year period. The LTI Plan Awards of executive directors of Mediclinic are subject to a further two-year holding period following the third anniversary of the date of grant, with no further performance conditions attached during the holding period.

On 19 May 2022, the Remuneration Committee approved the vesting of the LTI Plan Awards granted to the PDMRs listed in the table below at 12.1% of maximum based on the achievement against performance targets. These awards vested on 20 June 2022 and will be settled in cash based on the middle-market quotation of a share on 17 June 2022, being 457.40 pence per share. The amount settled includes the value of dividends attributable to the vested shares during the period between the date of grant and the date of vesting, being a total of 3.20 pence per share.

Name	Director/ PDMR	Number of Shares vested	Cash settlement (including dividend equivalents)
David John Hadley	PDMR	16 621	£76 556
Gert Cornelis Hattingh	PDMR	9 857	£45 401
Dr Dirk Cornelius le Roux	PDMR	7 739	£35 646
Dr Daniel Liedtke	PDMR	15 610	£71 900
Magnus Oetiker	PDMR	13 157	£60 601
Koert Hendrik Stefanus Pretorius	PDMR	10 760	£49 561
Dr René Toua	PDMR	7 739	£35 646
Greg van Wyk	PDMR	6 241	£28 746

The LTI Plan Awards granted to Dr Ronnie van der Merwe and Jurgens Myburgh on the same date will also vest at 12.1% of maximum based on the achievement against performance targets, equating to 45 185 and 24 981 shares, respectively. These awards will also be cash settled (as permitted under the

remuneration policy in place at the time and indicated in the Company's annual report for the financial year ended on 31 March 2019), as soon as practicable after vesting on 18 June 2024.

For further information, please refer to page 160 of the Company's annual report for the financial year ended 31 March 2022.

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.	Details of PDMR / person closely associated with them ('PCA')						
a)	Name	David John Hadley					
2.	Reason for the notification						
a)	Position / status	Chief Executive Officer – Mediclinic Middle East					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>£nil</td><td>16 621</td></tr></table>		Price(s)	Volume(s)	£nil	16 621
Price(s)	Volume(s)						
£nil	16 621						
d)	Aggregated information						
	Aggregated volume	16 621					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA						
a)	Name	Gert Cornelis Hattingh					
2.	Reason for the notification						
a)	Position / status	Group Chief Governance Officer – Mediclinic International plc					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£nil</td> <td>9 857</td> </tr> </table>		Price(s)	Volume(s)	£nil	9 857
Price(s)	Volume(s)						
£nil	9 857						
d)	Aggregated information						
	Aggregated volume	9 857					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA						
a)	Name	Dr Dirk Cornelius le Roux					
2.	Reason for the notification						
a)	Position / status	Group Chief Information Officer – Mediclinic International plc					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>£nil</td><td>7 739</td></tr> </tbody> </table>		Price(s)	Volume(s)	£nil	7 739
Price(s)	Volume(s)						
£nil	7 739						
d)	Aggregated information						
	Aggregated volume	7 739					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA						
a)	Name	Dr Daniel Liedtke					
2.	Reason for the notification						
a)	Position / status	Chief Executive Officer – Hirslanden					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£nil</td> <td>15 610</td> </tr> </tbody> </table>		Price(s)	Volume(s)	£nil	15 610
Price(s)	Volume(s)						
£nil	15 610						
d)	Aggregated information						
	Aggregated volume	15 610					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA						
a)	Name	Magnus Oetiker					
2.	Reason for the notification						
a)	Position / status	Group Chief Strategy Officer – Mediclinic International plc					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£nil</td> <td>13 157</td> </tr> </table>		Price(s)	Volume(s)	£nil	13 157
Price(s)	Volume(s)						
£nil	13 157						
d)	Aggregated information						
	Aggregated volume	13 157					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA						
a)	Name	Koert Hendrik Stefanus Pretorius					
2.	Reason for the notification						
a)	Position / status	Group Chief Operating Officer – Mediclinic International plc					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>£nil</td><td>10 760</td></tr> </tbody> </table>		Price(s)	Volume(s)	£nil	10 760
Price(s)	Volume(s)						
£nil	10 760						
d)	Aggregated information						
	Aggregated volume	10 760					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA						
a)	Name	Dr René Toua					
2.	Reason for the notification						
a)	Position / status	Group Chief Clinical Officer – Mediclinic International plc					
b)	Initial notification / amendment	Initial Notification					
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mediclinic International plc					
b)	LEI	2138002S5BSBIZTD5I60					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument	Ordinary Shares					
	Identification Code	GB00B8HX8Z88					
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan					
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£nil</td> <td>7 739</td> </tr> </table>		Price(s)	Volume(s)	£nil	7 739
Price(s)	Volume(s)						
£nil	7 739						
d)	Aggregated information						
	Aggregated volume	7 739					
	Price	£nil					
e)	Date of the transaction	20 June 2022					
f)	Place of the transaction	London Stock Exchange					

1.	Details of PDMR / PCA		
a)	Name	Greg van Wyk	
2.	Reason for the notification		
a)	Position / status	Chief Executive Officer – Mediclinic Southern Africa	
b)	Initial notification / amendment	Initial Notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Mediclinic International plc	
b)	LEI	2138002S5BSBIZTD5I60	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares	
	Identification Code	GB00B8HX8Z88	
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company’s Long-Term Incentive Plan	
c)	Price(s) and volume(s)		
		Price(s)	Volume(s)
		£nil	6 241
d)	Aggregated information		
	Aggregated volume	6 241	
	Price	£nil	
e)	Date of the transaction	20 June 2022	
f)	Place of the transaction	London Stock Exchange	

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom ('UK'), with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the UK and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet
+44 (0)333 300 1930

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries

FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK

Website: www.mediclinic.com

Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd